on bone scintigraphy

Purpose: This study evaluated the biodistribution of Tc-99m (V) DMSA in patients with superscans on bone imaging and defined its role in differentiating the underlying cause, Methods: Nine patients (five with metastatic and four with metabolic bone disease) with classical superscans were entered into the study. All patients had the necessary radiologic and biochemical studies and a final diagnosis was reached accordingly. Tc-99m M DMSA scintigraphy was performed 1 week after Tc-99m MDP whole-body bone imaging. Results: In four of five patients with widespread skeletal metastases, Tc-99m M DMSA scan showed diffusely increased bone uptake. In the remaining patient, the Tc-99m M DMSA scan showed a normal distribution pattern. All patients with metabolic bone disease had increased bone uptake on Tc-99m (V) DMSA scans, Conclusion: Tc-99m M DMSA shows increased bone uptake in patients having a superscan appearance in metastatic or metabolic bone disease, Tc-99m M DMSA imaging may play a role in the evaluation of patients with equivocal bone scan findings for a superscan.